Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of oral insulin ORMD-0801 in adults with type 2 diabetes and NASH/NAFLD
MOH_2020-11-05_009476Phase 2Recruiting
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) comparing ORMD-0801 with Placebo (2 arms). Primary endpoint: Safety of oral insulin ORMD-0801. Started Jul 2020; status: recruiting.
02
Drugs
ORMD-0801
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2020-11-05_009476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-05_009476.